2024临床研究行业概况 The Annual Clinical Trials Roundup 2024 Edition Promising Road to Recovery

CLINICAL

WhitePaper

TheAnnualClinicalTrialsRoundup

2024Edition:PromisingRoadtoRecovery

October2024

HeidiChen

AssociateDirector,Research&CommercialServices

TheAnnualClinicalTrialsRoundup

Introduction:TotalTrialActivities

Welcometothe2024editionofClinicalTrials

Roundup.Lastyear,weunveiledalandscape

ofincreasingcomplexity,culminatinginan

unprecedenteddeclineofclinicaltrialinitiations.Thebiopharmaindustryweatheredpost-

pandemicadjustments,enduredeconomic

hardshipsandslowedgrowthinmajormarkets,metregulatorypressurestoincorporate

diversity,equity,andinclusion(DE&I),and

sufferedtheimpactsofgeopoliticalconflicts.Lastyear,weconcludedwithacautiously

optimisticoutlook,anticipatingtheindustry’s

imminentbreakthroughinclinicaltrialinnovation.

ContinuingwithourannualtraditionofClinicalTrialsRoundupreview,the2024analysis

focusesonanoverviewofthePhaseI–III

clinicaltrialsthatinitiatedinthepriorcalendaryear(2023)acrossalltherapeuticareas(TAs)

comprehensivelycoveredbyTrialtrove,aswellasin-depthanalysesintothekeydiseases,

sponsoringcompanies,andgeographiesthat

impactthepharmaceuticalindustry.Wewill

surveytherecoveryinclinicaltrialactivity

thatoccurredasthepandemicgraduallyde-

escalatedtoanendemicandhowitreflectsthecurrentclinicallandscape.

AsofJune21,2024,Trialtrovecurated9,959

PhaseI–IIIclinicaltrials(Table1)investigatingatleastonedrugandwithadisclosedstart

datewithinthecalendaryearof2023,returninggrowthof9.4%,aremarkablerecoveryfrom

thedeclineobservedin2022.1Lookingattrialinitiationssince2020,thepandemic-relatedfluctuationsseemtohaveabatedsomewhat.Theriseandfallofinfectiousdisease(ID)

trialsreflectedtheindustry’sagilitytoadaptandmanagethechallengesbroughtbythe

pandemic.The9.4%increasein2023isa

notableachievement,surpassingtheaveragetotalgrowthof7.8%seenduring2017–23.

OverthelastthreeeditionsofClinicalTrials

Roundup,wehavesurveyedtrialinitiationswithandwithoutCOVIDtrialstogetasenseofhowthepandemicimpactedtrialinitiationsinotherTAs,namelythe“COVIDeffect.”Thedecline

in2020(-4%)madesense,while2021enjoyed

asurprisingcomebackat+22%.Then,trial

initiationsdippedbackdownto-6%in2022,

dueinparttotheharsheconomicenvironmentinbiopharma.Theyo-yohasswungbackupin

2023,exhibiting13%growthexcludingCOVID-19trials,alsoacutabovetheaveragegrowth

rateof7%fornon-COVIDtrialsduring2017–23.Willtheoscillatingcyclesbetweengrowthanddeclinecontinue,oristhebiopharmaindustryontracktofullrecovery?

1.Thedatasnapshotdatesforfull-yearactivityareJune21,2024;June26,2023;June23,2022;June14,2021;June12,2020;June5,2019;

June6,2018;andJuly6,2017.Duetodelaysinreportingoftrialactivity,countsforprioryearswillhavelikelygrownsincetheoriginaldatasnapshotdate.

2October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

Table1:PhaseI–IIIclinicaltrialactivitybyvolumeandgrowth,2017–23

Yearoftrialinitiation

2023

2022

2021

2020

2019

2018

2017

Trialcount

9,959

9,104

10,410

9,819

7,765

7,606

6,794

Year-on-yeargrowth(%)

9.4%

-12.5%

6%

26%

2%

12%

12%

Trialcount

(excludingCOVID-19trials)

9,654

8,541

9,077

7,424

7,765

7,606

6,794

Year-on-yeargrowth

(excludingCOVID-19trials,%)

13%

-6%

22%

-4%

2%

12%

12%

Source:Trialtrove,June2024

Industry-sponsoredtrials,whichaccounted

forover70%ofalltrialsinitiatedin2023,havebeenadrivingforceinclinicalresearch.Beforeanalyzingthedatatoforecastthetrajectory

ofclinicaltrialsactivity,let’sevaluatetheir

performanceoverthepastfiveyears,as

presentedinTable2.Thegrowthofindustry-sponsoredtrialsduringpre-pandemicyears

(2017–19)somewhatmirroredthatofthetotal

trialgrowthinTable1.Thattrendbrokein2020duetotheepicriseofnon-industry-sponsoredCOVIDtrials(26%totaltrialsvs.5%industry

trials).However,excludingCOVIDtrialcounts

significantlynarrowedthatgap(-4%totaltrialsvs.-8%industrytrials).Thehugegainof22%

fromexcludingCOVIDtrialsin2021waslargelynon-industry-sponsored,becauseonly6%wereaccountedforinindustry-sponsoredtrials.

Table2:PhaseI–IIIindustry-sponsoredtrialsbyvolumeandgrowth,2017–23

Yearoftrialinitiation

2023

2022

2021

2020*

2019*

2018*

2017*

Industry-sponsoredtrials

6,801

6,151

6,646

6,542

6,211

6,127

5,684

Year-on-yeargrowth(%)

11%

-7%

2%

5%

1%

8%

12%

Industry-sponsoredtrials(excludingCOVID-19trials)

6,611

5,807

6,027

5,709

6,202

-

-

Year-on-yeargrowth

(excludingCOVID-19trials,%)

14%

-4%

6%

-8%

N/A

-

-

*DataaccessedAugust2023Source:Trialtrove,June2024

3October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

2022hadfewertrialstartsacrossallfronts,butnowwearestartingtoseeindustry-sponsored

trialscatchingupasthenumberofCOVID

trialshasdiminished.2023certainlyreflects

astrongercomebackforindustry-sponsored

trials.Whilethe“COVIDeffect”petersoutoverthelasttwoyears,clinicalresearchinCOVID-19isheretostayasamainstaywithintheIDTA.

Goingforward,wemayhavereachedthepointwherewecanscrapthe“COVIDeffect”infutureanalyses.

Despitethatoptimisticnoteofaglowingreturntotrialstartsin2023,thereremainsasense

ofrestraint,astheoverallincreaseof9.4%stillfellshortofthe12%year-over-yeargrowth

inpre-pandemicyears.OurannualeditionofthePharmaR&DReview2024byIanLloyd

cheerfullyforecastedplentyofsunshinein

thepipelinetoholdoffstormcloudsonthehorizon.2Thetrajectoryoftheclinicaltrialsspaceisontheupaswell,withsunshinejustpeeringthroughtheclouds.Thecoldrealityofstormfrontstendstohitclinicaltrials

beforeitsimpacttricklesdowntoearly-stage

drugdiscovery,giventhesubstantialcostof

runningthetrials.Fundingisstillhardtocome

by,thoughtherearecreativeavenuesbeing

exploredthroughpartnerships;navigatingthe

regulatoryguidanceonDE&Iinclinicalplanninghasn’tgotteneasier;companieswillcontinue

tofacelegislativepressuresonpricing;and

weareseeinglowersuccessratesinclinical

developmentcomparedtoadecadeago.3Letusbravetherabbitholeandunravelwhat2023trialinitiationscantellus.

2.Citeline(2024)

PharmaR&DReview2024

3.Citeline(2024)

WhyAreClinicalDevelopmentSuccessRatesFalling?

4October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

ClinicalTrialActivitybyTherapeuticArea

ThelineupofTAsbytrialinitiationshas

remainedrelativelyunchangedsince2020,whentheCOVID-19pandemicboostedtheIDTAto

secondplace,anditremainsatthisrankingto

thisday.Oncologycontinuestohaveadistant

leadoverallotherTAs,ascancerremainsthe

mostprolificareaofresearch.IDtrialscontinuetorecedeastheyhavesince2021,narrowing

theIDTA’sleadoverCNS.Withtherenewed

boominneurologyandrecentsuccessinobesitydrugs,itmaysoonbeatoss-upbetweenCNS

andmetabolic/endocrinology(MET)tosnatchawaythesecondpositionfromtheIDTA.

AlthoughCNScurrentlyholdsthirdplace,it

onlyposted3%growthfrom2022,whileMET

achievedmoreimpressivegrowthof20%.Thecardiovascular(CVS)TAalsoexperiencedan

uptickof30%in2023.Boththeautoimmune/inflammation(A/I)andoncologyTAsachieved

similarclimbsat11%and10%growth,respectively.

Ophthalmology(OPH)andgenitourinary(GU)remainedthetwosmallestTAsinthemix,

switchingplacesfrom2022.ItisworthnotingthatthenumberofGUtrialswentupby100in2023,rakingin61%growth,thelargest

expansionrateofallTAs.

Figure1:PhaseI–IIIclinicaltrialinitiationsbytherapeuticarea4,2022–23

Oncology

InfectiousDisease

CNS

Autoimmune/Inflammation

Metabolic/Endocrinology

Cardiovascular

Genitourinary

Ophthalmology

723

1,465

1,711

1,437

1,397

1,360

1,228

1,239

1,029

938

3,718

3,394

20232022

264164

191169

01000200030004000

Trialcount

Source:Trialtrove,June2024

4.TrialsthatincludemultipleindicationsacrossdifferentTAswillbecountedforeachtargetedTA.Assuch,thesumoftrialcountsfortheeightTAswillbehigherthanthetotalnumberofPhaseI–IIItrialsstartedin2023.TrialcountsforIDincludeactivityfromvaccines(infectiousdiseases),whichisaseparateTAmodulewithinTrialtrove.Forthepurposesofthisanalysis,allIDactivityhasbeencombinedintoasingleTA.

5October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

PhasesofTrialActivities

Ahealthyclinicalpipelineistypically

characterizedbyabalanceddistributionof

drugsacrossthephases,withhigheractivityintheearlierphasesandgraduallyshrinkingasthecompoundsadvancethroughattrition.Thatisexactlywhatweseeoverthelasttwoyears,thoughweseeaslightlyhighernumberofPhaseItrialsin2023.Figure2Aoffersa

normalizedviewofphasedistributions,showingthepercentageofeachphaseagainsttotal

trialsintheirrespectiveyears.TheproportionofPhaseIIandPhaseIIItrialsappearedto

experiencelittlechange,whereasPhaseItrialsgrewby3.3%,asignofsustainedinnovationintheclinicalpipeline.

Figure2A:DistributionofPhaseI–IIIclinicaltrialsbytrialphase,2022–23

50%

45%

40%

35%

30%

25%

20%

15%

10%

5%

0%

44.3%

41%

30.1%31%

16%

15.1%

9%

7.9%

3%

2.7%

PhaseIPhaseI/IIPhaseIIPhaseII/IIIPhaseIII

20232022

Source:Trialtrove,June2024

6October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

7October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

AcloserlookattheTAcompositionsbyphaseinFigure2BrevealsthatthedomineeringpresenceofoncologyinearlyphasesshrankinPhaseIII,reflectingthepersistentchallengeinthisTAto

survivebeyondPhaseIIclinicaldevelopment.TheCVS,CNS,andA/ITAssawatleasttwice

asmanyPhaseIstudiesasPhaseIIstudies,

suggestingearlierattritionthanoncology.EarlydiscontinuationsaresuggestiveoftheR&D

strategywherebycompaniesmakego/no-godecisionsearlier,thuscuttingtheirlossesof

runningmoreandlargertrials.

Figure2B:2023trialsbyphaseandTA

5,000

4,500

4,000

3,500

3,000

2,500

2,000

1,500

1,000

500

0

I

I/II

IIII/IIIIII

Oncology

CNS

Autoimmune/Inflammation

Metabolic/Endocrinology

InfectiousDisease

Cardiovascular

Genitourinary

Ophthalmology

Source:Trialtrove,June2024

TheAnnualClinicalTrialsRoundup

TopDiseaseAreasof2023TrialInitiations

Eachyearwesurveythetopcontendersof

themostactivediseasesinclinicaltrials.The

No.1spotinFigure3wasfinallyreclaimedby

unspecifiedsolidtumorin2022,anditretaineditsrankin2023.Thebiggestupsetisnon-smallcelllungcancer(NSCLC)ascendingtosecondplace,helpingpushCOVID-19downtherank

fromsecondtoeighthplace(Table3).Oncologydiseasescomprisedsixofthetop10listin

2023.Type2diabetes(T2D)hadanimpressiveascentfromsixthtothirdplacethisyear.TheestablishedsuccessofOzempic,Trulicity,and

Farxigabroughtfreshfocustothisdiseasearea,withadditionalpromisingcontendersMounjaroandRybelsusemergingwithimpressive

performancesin2023.Bothrespiratory

infectionsandcolorectalcancermoveduptwo

positions,butnon-Hodgkin’slymphoma(NHL)fellbytwo.Thisyear,wewelcomednewjoinershypertensionandpancreaticcancertoroundoutthetop10,displacingrespiratoryvaccinesandnociceptivepainfromlastyear.

Giventhelargeoncologypresenceinthetop10diseases,mostofitsclinicaldevelopment

isearly-phaseheavy(PhaseI–II).Unspecified

solidtumor,NSCLC,breastcancer,and

colorectalcancerarethehotbedsoftrial

initiations.T2Dalsohadsignificanttrial

initiationsinPhaseI.AsweturnoureyetoPhaseIIItrials,TAdiversitybecomesmoreprominent,giventhetopdiseaseshere

consistedofT2D,breastcancer,andrespiratoryinfections.

UnspecifiedSolidTumor

NSCLC

Type2Diabetes

Breastcancer

RespiratoryInfections

Colorectalcancer

Lymphoma,Non-Hodgkin's

COVID-19

Hypertension

Pancreaticcancer

Figure3:Top10diseasesinPhaseI–IIIclinicaltrialinitiations,2023

271

359

354

305

295

425

424

404

578

516

0100200300400500600

II/IIIIII/IIIIII

Source:Trialtrove,June2024

8October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

ThesteadyupwardtrendofrarediseaseR&Dalsosufferedasetbackin2022,with13%fewertrialinitiationsthanthepreviousyear,wiping

awaythepost-pandemicreboundobservedin2021(Figure4).

Table3:Top10diseasesandtheirrankingcomparisonsto2022

Diseases

#oftrials

Rank(2022rank)

UnspecifiedSolidTumor

578

1(1)

NSCLC

516

2(3)

Type2Diabetes

425

3(6)

Breastcancer

424

4(4)

RespiratoryInfections

404

5(7)

Colorectalcancer

359

6(8)

Lymphoma,Non-Hodgkin's

354

7(5)

COVID-19

305

8(2)

Hypertension

295

9(12)

Pancreaticcancer

271

10(15)

Source:Trialtrove,June2024

9October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

AWordAboutRareDiseaseTrials

Speakingofthetopdiseases,wemustnot

overlooktheimportantprogressachievedin

therarediseaseareas.Citelinedefinesarare

diseaseasonewithaprevalenceofbelow1in

2,000peopleintheEUoraffectingfewerthan

200,000peopleintheUS(equivalenttoaround1in1,600people).ThesteadyclimboverthelastdecadeinFigure4peakedin2021with3,581

trialsbutdippedbackdowntopre-pandemic

levelsin2022and2023.Asclinicaltrialsbecomemorecomplexandexpensiveovertheyears,

thisisevenmorethecaseforrarediseases,

astheseinherentlynicheareasfaceharder

circumstanceswithpatientenrollment,retention,andfollow-up.Thesteepsetbackofrarediseasetrialsin2022(-14%)wipedawaytherebound

gainin2021;however,thedeclinein2023was

lesssevereat-5%with2,914trials.Rarediseasetrialsrepresented29.3%ofthetotal2023trial

initiations,whichisconsistentwithitsproportioninprioryears,rangingbetween27%and30%.

Figure4:RarediseasetrialinitiationsinPhaseI–III,2011–23

Trialcount

248

2,454

2,661

2,054

2,101

Y-O-Ydelta

9

3,581

TrialcountY-O-Ydelta

2,921

3,006

3,16

3,115

3,074

2,914

2,026

2,

2011201220132014201520162017201820192020202120222023

4,000

3,500

3,000

2,500

2,000

1,500

1,000

500

0

20%

15%

10%

5%

0%

-5%

-10%

-15%

-20%

Year

Source:Trialtrove,June2024

Ourpastsurveysoftherarediseasetrial

landscapepointedtotheoncologyTAbeing

wherethemostresearcheffortsreside,andthisyearisnodifferent.ThetopfiverarediseasesinFigure5happenedtobethesametopfivewe

featuredinthepreviousedition.Historically,NHL

hasbeenthetopraredisease,butin2023itis

theonlyindicationinthetopfivethatdecreased

intrialnumber,whereastheotherfourall

experiencedmodestincreases,withpancreaticcancerhavingthelargestdifferential.

10October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

Figure5:Topfiveindicationsinrarediseases,bytrialinitiations,2022–23

400

350

300

250

200

150

100

50

0

367

354

271

257

247

223

227

228

207

206

NHLPancreaticCancerHead/NeckCancerEsophagealCancerLiverCancer

20232022

Source:Trialtrove,June2024

IfweturnourfocusonrarediseasesoutsideoftheoncologyTA,Table4showsquitea

diversifiedportfolioandtightercompetitionamongthetop10.

Table4:Top10rarediseasesinnon-oncologyTAsbytrialinitiations,2023

Disease

#oftrials2023(2022)

ImmuneThrombocytopenia(ITP)

45(25)

Tuberculosis(TB)

43(33)

PulmonaryHypertension

39(NA)

AmyotrophicLateralSclerosis

28(35)

MuscularDystrophy

24(24)

Thalassemia

23(13)

CysticFibrosis

22(26)

SickleCellDisease

22(28)

Dermatomyositis/Polymyositis

16(NA)

Scleroderma

16(20)

Source:Trialtrove,June2024

11October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

ThegeographicallandscapeofrarediseasetrialsinFigure6highlightsChina’spersistent

dominanceinthisspace,givenitsstrongfocusintheoncologyTA.

China

UnitedStates SpainAustralia

FranceUnitedKingdom

Germany Japan ItalyCanada

Figure6:Top10countriesofrarediseaseclinicaltrialsin2023

17

160

230

220

217

210

208

199

6

1,015

1,267

0200400600800100012001400

Source:Trialtrove,June2024

However,thetopindustrysponsorsofrare

diseasetrialsinFigure7showsthetopfive

spotsarefilledbywesterntop20pharma

companies,withonlytwoChinesecompanies,JiangsuHengruiandSinoBiopharmaceutical,

exertingtheirpresencewithinthetop10.

ThislandscapereflectstheimpactofChina’sNationalMedicalProductsAdministration

(NMPA)reformsthatincentivizeforeigndrugdevelopmentandclinicaltrials.

12October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

Figure7:Topindustrysponsorsinrarediseaseclinicaltrials,2023

Roche

AstraZeneca

Merck&Co.

Bristol-MyersSquibbPfizer

JiangsuHengruiPharmaceuticalsSinoBiopharmaceuticalNovartis

AbbVie

Incyte

Johnson&JohnsonSanofi

64

58

53

32

32

31

29

28

26

22

22

21

0102030405060

II/IIIIII/IIIIII

70

Source:Trialtrove,June2024

Thegrowingimportanceofrarediseaseshas

pulledtogethercommunitylobbyists,patient

advocates,anddrugdevelopers,drivingthe

influencebehindtheUSFDA’screationofthe

raredisease“hub,”whichwillactasaCenter

ofExcellence,muchliketheOncologyCenter

ofExcellencethattheFDAinstitutedin2016.5

Thehubwillaimtoprovideneededregulatory

flexibilityforrarediseasedrugdevelopment.

Thedecreaseintrialinitiationsduring2023mayseemtohinderpost-pandemicrecovery,but

thehub’semergencecouldreignitemomentum.

RarediseaseR&Dremainsastrongfocus

inthehealthcareindustrybecauseofthe

debilitatingnatureoftheseconditions.The

numberoftargetedrarediseasescontinues

torise,reaching761in2023,asreportedby

Citeline’sPharmaR&DAnnualReview2024.2Thistranslatestoa7.6%riseinthenumberofdrugsunderdevelopmentfromtheprioryear,representing30%ofalldrugsinthepipeline.

5.Citeline(2024)

USFDACreatingRareDisease‘Hub’ToServeAsCenterOfExcellence

13October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

KeyIndustrySponsorsin2023TrialInitiations

Thetop10industrysponsorsmaintaineda

relativelystablecompositionwithminorrank

fluctuationsuntil2023,whenamoredynamic

landscapeemerged.AstraZenecaregainedits

crownwith139trialsafteritwasedgeddownbyMerck&Co.in2022(Table5).Pfizerclimbedtothesecondpositionwith128trials,asignificantascentfromitsconsistentmid-tablerankinginpreviousyears,narrowlyoutpacinglastyear’s

championMerck&Co.,aswellasRoche.Merck&Co.’sdecreaseinPhaseIItrialsledtothelossofitsNo.1position(Figure8).

ChinesepharmacompanyJiangsuHengrui

Pharmaceuticalscontinueditsmid-tierstandingamongthetop10.2023welcomedanewcomer

tothetop10,SinoBiopharmaceutical,whichovertooktwotop10pharmacompanies,

NovartisandJohnson&Johnson.EliLilly

climbeduptwopositionsfromitscustomarylowerechelonofthetop10pharmaceuticalcompanies,atrajectoryundoubtedly

acceleratedbythesuccessofitstirzepatideanddonanemabprograms.

Table5:Rankingsoftop10industrytrialsponsors,2023

Sponsor

Rank2023(2022)

#oftrials2023(2022)

AstraZeneca

1(2)

139(122)

Pfizer

2(4)

128(112)

Merck&Co.

3(1)

126(148)

Roche

3(3)

126(114)

JiangsuHengruiPharmaceuticals

5(5)

120(106)

Bristol-MyersSquibb

6(8)

98(84)

EliLilly

7(9)

95(79)

SinoBiopharmaceutical

8(11)

85(61)

Novartis

9(6)

74(92)

Johnson&Johnson

10(7)

66(85)

Source:Trialtrove,June2024

TrialdistributionsacrossPhaseI–III

developmentamongthetop10sponsorsrevealedthatPfizerhadthemostPhaseI

trials(58trials),followedcloselybyChinese

companiesJiangsuHengrui(53trials)andSinoBiopharmaceutical(52trials).Earlier,Figure2ArevealedthatPhaseItrialscomprisedover44%ofalltrialinitiationsin2023;consequently,itis

unsurprisingthattheydominatetrialactivity

amongthetop10industrysponsors.RocheandMerck&Co.ledwiththemostPhaseIItrials,

whichwereprimarilydedicatedtotheoncologyTA.AstraZenecareignedinPhaseIIItrial

initiationsinboth2022(33trials)and2023(43trials).

14October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

Figure8:Top10industrysponsorsbytrialdistributionsinPhaseI–III,2022–23

2023

AstraZeneca

Pfizer

Merck&Co.

Roche

JiangsuHengruiPharmaceuticals

Bristol-MyersSquibb

EliLilly

SinoBiopharmaceutical

Novartis

Johnson&Johnson

139

74

66

95

85

98

128

126

126

120

020406080100120140

II/IIIIII/IIIIII

160

Merck&Co.

AstraZeneca

Roche

Pfizer

JiangsuHengruiPharmaceuticals

Novartis

Johnson&Johnson

Bristol-MyersSquibbEliLilly

GlaxoSmithKline

2022

70

92

85

84

79

114

112

106

122

148

020406080100120140160

II/IIIIII/IIIIII

Source:Trialtrove,June2024

15October2024Copyright©⃞2024Citeline,aNorstellacompany.(Unauthorizedphotocopyingprohibited).

TheAnnualClinicalTrialsRoundup

TopDiseaseFocusby10MostActiveSponsors

Wenowexaminetheprimarydiseasefocusofthetop10sponsorsindetail,comparingtheirongoingcommitmentswithanyshiftsindirection.Table6summarizesthetop

threediseasesforeachofthetop10industry

sponsorsin2022and2023.Thenumberof

uniquediseaseshasbouncedbetween17and

22overthelastfiveyears,with16beingthe

finalnumberin2023.Thediminisheddiversity

indiseaseportfoliosindicatesconvergingor

renewedcompetitioninsomediseaseareas,asthepandemicnolongerinfluencestheprimarydiseaselandscapehere.Previously,wesawsixoutofthetop10sponsorsretaintheirNo.1

disease,whereasthisyearonlyNovartisand

Johnson&JohnsonkepttheirNo.1commitment

unchanged,inbreastcancerandmultiplemyeloma,respectively.

Theoverwhelmingpresenceofoncologicaldiseasescontinuestobeevidentamongthetop10industrysponsors.Companieslike

AstraZeneca,Merck&Co.,Roche,Jiangsu

Hengrui,BristolMyersSquibb,andSino

Biopharmaceuticalallhaverobustoncologypipelinestosustaintheirtop-rankingstatus.NSCLCremainsthehighestprioritydiseaseamongthetop10sponsors,followedby

unspecifiedsolidtumorandbreastcancer.

Nearlyallcompaniesprioritizedoncologyasoneoftheirtopthreetherapeuticareasforclinical

trialsin2023.EliLillydivergedfromthetrend

withitssteadfastcommitmenttoobesity,T2D,anddyslipidemiainbothyears.Followingthecontainmentofthepandemic,PfizerinvestedinoncologywithitsSeagenacquisition,whichenabledittoinh